Antonio Aguilera,Sara Pereira,Ana Fuentes et al.
Antonio Aguilera et al.
Santosh Kumar K Y,Praveen Kumar R Bhat,Chandrashekar J Sorake
Santosh Kumar K Y
Diversity in clinical trials: an opportunity and imperative for community engagement [0.03%]
临床试验中的多样性：社区参与的机会与必要性
Darrell M Gray nd,Timiya S Nolan,John Gregory et al.
Darrell M Gray nd et al.
Loren Galler Rabinowitz,Lauren Tal Grinspan,Michelle Kang Kim
Loren Galler Rabinowitz
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial [0.03%]
RO7049389（核心蛋白别构调节剂）在慢性乙型肝炎病毒感染患者中的安全性、药代动力学和抗病毒活性：一项多中心随机双盲安慰剂对照的Ⅰ期临床试验
Man-Fung Yuen,Xue Zhou,Edward Gane et al.
Man-Fung Yuen et al.
Background: RO7049389, a hepatitis B virus (HBV) core protein allosteric modulator being developed for the treatment of chronic HBV infection, was found to be safe and well tolerated in healthy participants (part 1 of thi...
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis [0.03%]
用于预防内镜逆行胰胆管造影后急性胰腺炎的非甾体抗炎药、静脉输液、胰管支架或其组合：系统评价和网状meta分析
Venkata S Akshintala,Christina J Sperna Weiland,Furqan A Bhullar et al.
Venkata S Akshintala et al.
Background: Non-steroidal anti-inflammatory drugs (NSAIDs), intravenous fluid, pancreatic stents, or combinations of these have been evaluated in randomised controlled trials (RCTs) for the prevention of post-endoscopic r...
Olav Dalgard,Håvard Midgard,Knut Boe Kielland
Olav Dalgard
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study [0.03%]
冰岛治疗预防丙型肝炎计划（TraP HepC）前36个月的关怀cascade：一项基于人口的研究
Sigurdur Olafsson,Ragnheidur H Fridriksdottir,Thorvardur J Love et al.
Sigurdur Olafsson et al.
Background: WHO has set targets to eliminate hepatitis C virus (HCV) infection as a global health threat by 2030 through a 65% reduction in HCV-related deaths and 80% reduction in HCV incidence. To achieve these goals, WH...
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study [0.03%]
阿达木单抗治疗中重度溃疡性结肠炎儿科患者的有效性和安全性（ENVVISION I）：一项随机、双盲、安慰剂对照III期试验
Nicholas M Croft,William A Faubion Jr,Subra Kugathasan et al.
Nicholas M Croft et al.
Background: Biologic treatment options are limited for children with ulcerative colitis. The aim of this study was to assess the safety and efficacy of adalimumab in children with moderate-to-severe ulcerative colitis. ...